BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17725429)

  • 1. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
    Meireles AM; Preto A; Rocha AS; Rebocho AP; Máximo V; Pereira-Castro I; Moreira S; Feijão T; Botelho T; Marques R; Trovisco V; Cirnes L; Alves C; Velho S; Soares P; Sobrinho-Simões M
    Thyroid; 2007 Aug; 17(8):707-15. PubMed ID: 17725429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
    Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
    Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fine-needle aspiration cytology of thyroid nodules: molecular diagnostics in a routine diagnostic setting].
    Eszlinger M; Neustadt M; Ruschenburg I; Neumann A; Franzius C; Adam S; Bacher K; Hach A; Hammoser R; Langvogt C; Molwitz T; Paschke R
    Dtsch Med Wochenschr; 2014 Mar; 139(10):476-80. PubMed ID: 24570192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
    Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.
    Pallante P; Visone R; Croce CM; Fusco A
    Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
    Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
    J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma.
    Anania MC; Miranda C; Vizioli MG; Mazzoni M; Cleris L; Pagliardini S; Manenti G; Borrello MG; Pierotti MA; Greco A
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1591-600. PubMed ID: 23928665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
    Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.
    Pilli T; Prasad KV; Jayarama S; Pacini F; Prabhakar BS
    Thyroid; 2009 Dec; 19(12):1333-42. PubMed ID: 20001716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.